Patents by Inventor Stephen B. Ruddy

Stephen B. Ruddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080241070
    Abstract: Disclosed are redispersible fibrate, such as fenofibrate, dosage forms. Also disclosed are in vitro methods for evaluating the in vivo effectiveness of fibrate, such as fenofibrate, dosage forms. The methods utilize media representative of in vivo human physiological conditions.
    Type: Application
    Filed: March 28, 2008
    Publication date: October 2, 2008
    Inventors: Tuula A. Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins, Niels P. Ryde
  • Publication number: 20080213371
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: February 11, 2008
    Publication date: September 4, 2008
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth lain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20080138424
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 12, 2008
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Patent number: 7320802
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: January 22, 2008
    Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Patent number: 7276249
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: October 2, 2007
    Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Patent number: 7198795
    Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: April 3, 2007
    Assignee: Elan Pharma International Ltd.
    Inventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
  • Patent number: 6908626
    Abstract: Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: June 21, 2005
    Assignee: Elan Pharma International Ltd.
    Inventors: Eugene R. Cooper, Stephen B. Ruddy
  • Publication number: 20040087656
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: October 27, 2003
    Publication date: May 6, 2004
    Applicant: Elan Pharma International, Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Publication number: 20040057993
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: September 23, 2003
    Publication date: March 25, 2004
    Applicant: Elan Pharma International Limited
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20040058009
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: October 27, 2003
    Publication date: March 25, 2004
    Applicant: Elan Pharma International, Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Publication number: 20040029099
    Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
    Type: Application
    Filed: December 20, 2002
    Publication date: February 12, 2004
    Applicant: Elan Pharma International Ltd.
    Inventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
  • Publication number: 20040013613
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: January 15, 2003
    Publication date: January 22, 2004
    Inventors: Rajeev A Jain, Stephen B Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20030224058
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: February 21, 2003
    Publication date: December 4, 2003
    Applicants: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Publication number: 20030137067
    Abstract: Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.
    Type: Application
    Filed: October 11, 2002
    Publication date: July 24, 2003
    Applicant: Elan Pharma International Ltd.
    Inventors: Eugene R. Cooper, Stephen B. Ruddy
  • Patent number: 6592903
    Abstract: Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: July 15, 2003
    Assignee: Elan Pharma International Ltd.
    Inventors: Niels P. Ryde, Stephen B. Ruddy
  • Publication number: 20030054045
    Abstract: Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.
    Type: Application
    Filed: June 21, 2002
    Publication date: March 20, 2003
    Applicant: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, W. Mark Eickhoff, Kathleen J. Illig, Pramod Sarpotdar, Stephen B. Ruddy
  • Publication number: 20020110597
    Abstract: Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: February 15, 2002
    Publication date: August 15, 2002
    Applicant: Elan Pharma International Ltd.
    Inventors: Niels P. Ryde, Stephen B. Ruddy
  • Patent number: 6432381
    Abstract: Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: August 13, 2002
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, W. Mark Eickhoff, Kathleen J. Illig, Pramod Sarpotdar, Stephen B. Ruddy
  • Patent number: 6375986
    Abstract: Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: April 23, 2002
    Assignee: Elan Pharma International Ltd.
    Inventors: Niels P. Ryde, Stephen B. Ruddy
  • Patent number: 6316029
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: November 13, 2001
    Assignee: Flak Pharma International, Ltd.
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd